As I've mentioned numerous times by now, Canada is right at the doorstep of becoming the first G7 nation where the use of recreational cannabis is legalized for the entire country.
I can't emphasize enough how big this is.
In fact, the recreational marijuana market in Canada could be valued at anywhere between $5 billion and $10 billion per year.
The company that I'll be talking about today is one that I first recommended to my Nova-X Report readers way back in 2016.
The company has recently gone through some exciting developments and can take advantage of the massive potential of the marijuana market.
You see, on May 24, the company uplisted, and its shares are currently trading on the New York Stock Exchange, in addition to trading on the Toronto Stock Exchange.
Here's why this move will maximize this stock's profit potential.
You see, uplisting will benefit the stock's price, liquidity, and potential appreciation.
First, by moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base.
Second, the exchanges and market participants are more likely to offer greater liquidity and price discovery and be more active in supporting and trading the stock.
So let's take a look at this Canadian pot stock and its potential for massive gains…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.